Skip to content

Evaluate the safe and efficacy of Hair removal spray

A open label, clinical study to evaluate the efficacy and safety of hair removal spray on healthy adult subjects - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/12/078553
Enrollment
30
Registered
2024-12-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Hair Removal spray: • Keep the bottle 10-15 cm away and spray it on the skin • Wait for 8-10 minutes • Under running water, use a spatula in the opposite direction of hair growth • G

Sponsors

Pontika Aerotech Limited
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects in generally good health 2. Subjects in the age group of 18-60 years. 3. Subjects with moderate hair growth on forearm, legs and pubic area. 4. Subjects without any cuts, marks and open wounds on forearm, legs and pubic area. 5. Subjects have not used a similar product for the last four weeks.

Exclusion criteria

Exclusion criteria: 1. Subjects who have pre-existing or dormant dermatologic conditions (e.g., psoriasis, rosacea, rashes, eczema and severe excoriations). 2. Patients of vulnerable group (children, lactating mother, elderly above 80 years, handicapped, seriously ill, mentally challenged). 3. Subjects with known allergies or sensitivities to cosmetic products, toiletries or its components like fragrances, preservatives, etc. 4. History of allergy to the test product.

Design outcomes

Primary

MeasureTime frame
1. Hair count reduction in the applied area by comparing with Photographs. 2. Subjects assessment of comfort associated with treatments using a VAS scale. Subjects satisfaction with hair removal treatments and assessment of improvement using a ten point scale. 3. The skin will be evaluated for signs of irritation identified under Erythema and odema, using Draizes scale. 4. a. Ease of application or usage b. Stickiness c. Greasiness and d. Ease of spreading. 5. Product evaluation and product performance feedback questions will be obtained from the participants.Timepoint: Visit 1 (day 1) and visit 2 (Day 2)

Secondary

MeasureTime frame
To demonstrate safety and tolerability of study product by Clinical AEs (If any) Safety and tolerability evaluation criteria: 1. Adverse events and serious adverse events during the study period 2. Brief clinical examination Timepoint: Visit 1 (day 1) and visit 2 (Day 2)

Countries

India

Contacts

Public ContactDr Gayathri Sivakumar

DK Elite Health Care Centre

saheerose@gmail.com9843591097

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026